A phase 2/3 study of ABP 300 for the early treatment of patients with mild or moderate COVID-19
Latest Information Update: 23 Dec 2020
At a glance
- Drugs ABP 300 Abpro Therapeutics (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Abpro Therapeutics
- 23 Dec 2020 New trial record
- 16 Dec 2020 According to an Abpro media release, the company expects to report data from this study in Q1 2021.
- 16 Dec 2020 According to an Abpro media release, the company has initiated this study. The first trial site has been opened with the remainder to follow in 2021.